Abstract：Objective To explore the expression level of typeⅡGolgi protein 73 (GP73) in hepatocellular carcinoma (HCC)and its correlation with the prognosis of HCC. Methods Sixty-five patients with HCC, 60 health check-up individuals and 62 patients with chronic moderate hepatitis B were selected from Department of Hepatobiliary Surgery, Jinzhou Central Hospital to serve as the case group, the healthy control group and the case group of chronic moderate hepatitis B respectively. Their general information and clinical pathological data were collected. ELISA was used to determine the (preoperative) serum GP73 level, and then the case group was further divided into the high GP73 subgroup and the low GP73 subgroup according to the preoperative serum GP73 level with the median principle. Liver function and tumor size and grading were compared between the two subgroups. Serum AFP concentration was detected by particles-based chemiluminescence immunoassay enzyme particles (CLEIA), and the correlation between AFP and GP73 was analyzed. A long-term follow-up was conducted in the postoperative HCC patients, and their survival rates were recorded and statistically analyzed. Results A comparison between the case group and the healthy control group, the case group of chronic moderate hepatitis B showed that the proportion of patients with hepatitis B (69.2%) and the AFP levels in the case group were significantly higher than those of the healthy control group and the case group of chronic moderate hepatitis B (both P<0.01). The serum GP73 level was significantly higher in the case group than in the healthy control group and the case group of chronic moderate hepatitis B. A comparison between the two subgroups revealed that there were statistically significant differences in the numbers of cases with liver function grades A, B and C based on Child-Pugh grading, the size of the tumor and TNM classification between the high GP73 subgroup and the low GP73 subgroup (all P<0.05). Hepatic reservation function and tumor progression stages of the high GP73 subgroup were inferior to those of the low GP73 subgroup, and the postoperative 60-week survival rate showed a statistically significant difference between the two subgroups(P<0.05). There was a significantly po-sitive correlation between GP73 and AFP levels in the case group (r=0.876, P<0.05). Conclusions GP73 is highly expressed in the patients with HCC; moreover, it is closely related to the level of AFP, but negatively correlated with the survival rate. GP73 may be used as one of the biomarkers for the prognosis of HCC.
黄飞, 贺新祥, 刘文俊, 杨忠民, 王光链. Ⅱ型高尔基体膜蛋白73在肝细胞肝癌中的水平及与肝细胞肝癌预后的相关性[J]. 实用预防医学, 2017, 24(7): 882-885.
HUANG Fei, HE Xin-xiang, LIU Wen-jun, YANG Zhong-min, WANG Guang-lian. Serum level of type Ⅱ Golgi protein 73 in hepatocellular carcinoma and its correlationwith the prognosis of hepatocellular carcinoma. , 2017, 24(7): 882-885.
[1] Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma.Prevention of hepatocellular carcinoma in the Asia-Pacific region:consensus statements[J] . J Gastroenterol Hepatol, 2010, 25:657-663. [2] Zhu RX, Seto WK, Lai CL, et al.Epidemiology of hepatocellular carcinoma in the Asia-Pacific Region[J] . Gut Liver, 2016,10(3):332-339. [3] Belghiti J, Fuks D. Liver resection and transplantation in hepatocellular carcinoma[J] . Liver Cancer, 2012,1(1):71-82. [4] Cheah LY, Chow KHP. Liver transplantation for hepatocellular carcinoma:an appraisal of current controversies[J] . Liver Cancer, 2012, 1(3-4):183-189. [5] Farinati F, Marino D, De Giorgio M, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma:both or neither[J] . Am J Gastroenterol, 2006, 101:524-532. [6] 谢延,陈晓燕,蒋英. 高尔基体蛋白73预警肝癌的应用研究[J] . 实用预防医学,2011,18(11):2042-2043. [7] Sai W, Wang L, Zheng W, et al. Abnormal expression of Golgi protein 73 in clinical values and their role in HBV-related hepatocellular carcinoma diagnosis and prognosis[J] . Hepat Mon,2015,15(12):e32918. [8] 赵岩,李勇,胡宝山,等. 高尔基体蛋白73在肝细胞癌诊断及预测疾病进展中的作用[J] . 中华医学杂志,2014,94(5):390-392. [9] Block TM,Comunale MA, Lowman M, et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans[J] . Proc Natl Acad Sci USA,2005,102(3):779-784. [10] Janevska D, Chaloska-Ivanova V, Janevski V. Hepatocellular carcinoma: risk factors, diagnosis and treatment[J] . Open Access Maced J Med Sci,2015,3(4):732-736. [11] Knudsen ES, Gopal P, Singal AG. The changing landscape of hepatocellular carcinoma:etiology, genetics, and therapy[J] . Am J Pathol,2014,184(3):574-583. [12] 周峥,解长佶,曾志平,等. 173例肝癌切除术后早期复发时间分析[J] . 中华肝胆外科杂志,2014,20(10):746-747. [13] 张博恒,杨秉辉,沈月芳. 甲胎蛋白联合实时超声检查作为肝癌筛查试验的评价[J] . 中华医学杂志,1999,79(11):844. [14] Hu B, Tian X, Sun J, et al. Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma:a meta-analysis[J] . Int J Mol Sci,2013,14(12):23559-23580. [15] Yang J, Li J, Dai W, et al. Golgi protein 73 as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis[J] . Exp Ther Med,2015,9(4):1413-1420. [16] Zhang YL, Zhang Y C, Han W, et al. Effect of GP73 silencing on proliferation and apoptosis in hepatocellular cancer[J] . World J Gastroenterol,2014,20(32):11287-11296. [17] Hou SC, Xiao MB, Ni RZ,et al. Serum GP73 is complementary to AFP and GGT-II for the diagnosis of hepatocellular carcinoma[J] . Oncol Lett, 2013,6(4):1152-1158. [18] Qiao Y, Chen J, Li X,et al. Serum gp73 is also a biomarker for diagnosing cirrhosis in population with chronic HBV infection[J] . Clin Biochem, 2014,47(16-17):216-222. [19] Mao Y, Yang H, Xu H, et al. Golgi protein 73(GOLPH2) is a valuable serum marker for hepatocellular carcinoma[J] . Gut,2010,59(12):1687-1693. [20] 高文斌,肖帅,雷雄,等. 孤立性大肝癌患者肝切除术后长期预后因素分析[J] . 中华外科杂志,2016,54(7):492-497.
2017, Vol. 24 
